Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nowotwory. Journal of Oncology
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Editorial Office Manuscript Submission Reviewers 2023 Best Original Paper Award

open access

Vol 73, No 1 (2023)
Review paper
Published online: 2022-12-16
View PDF Download PDF file
Get Citation

Radiotherapy and immunotherapy

Ewa Sierko12
DOI: 10.5603/NJO.a2022.0062
·
Nowotwory. Journal of Oncology 2023;73(1):22-31.
Affiliations
  1. Radiotherapy Department 1, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland
  2. Department of Oncology, Medical University of Bialystok, Bialystok, Poland

open access

Vol 73, No 1 (2023)
Radiotherapy in the combined treatment
Published online: 2022-12-16

Abstract

Radiation therapy is one of the standard treatment methods for cancer patients. Apart from killing cancer cells, it produces a modulation effect on local and systemic disease. Recently, immunotherapy, aiming mainly to immune checkpoint blockade, has become widely used in many clinical situations. Experimental and clinical studies indicate that the combination of both radiation therapy and immunotherapy may be beneficial in the cancer patient population in different clinical scenarios. Durvalumab maintenance therapy after radiochemotherapy in stage III non-small-cell lung cancer (NSCLC) patients was introduced to standard clinical care. The paper discusses the pathogenesis of the mutual interaction between radiation therapy and immunotherapy, as well available preclinical and clinical data concerning this promising treatment combination.

Abstract

Radiation therapy is one of the standard treatment methods for cancer patients. Apart from killing cancer cells, it produces a modulation effect on local and systemic disease. Recently, immunotherapy, aiming mainly to immune checkpoint blockade, has become widely used in many clinical situations. Experimental and clinical studies indicate that the combination of both radiation therapy and immunotherapy may be beneficial in the cancer patient population in different clinical scenarios. Durvalumab maintenance therapy after radiochemotherapy in stage III non-small-cell lung cancer (NSCLC) patients was introduced to standard clinical care. The paper discusses the pathogenesis of the mutual interaction between radiation therapy and immunotherapy, as well available preclinical and clinical data concerning this promising treatment combination.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

radiation therapy; radiotherapy; immunotherapy; checkpoint inhibitors; cancer

About this article
Title

Radiotherapy and immunotherapy

Journal

Nowotwory. Journal of Oncology

Issue

Vol 73, No 1 (2023)

Article type

Review paper

Pages

22-31

Published online

2022-12-16

Page views

2616

Article views/downloads

200

DOI

10.5603/NJO.a2022.0062

Bibliographic record

Nowotwory. Journal of Oncology 2023;73(1):22-31.

Keywords

radiation therapy
radiotherapy
immunotherapy
checkpoint inhibitors
cancer

Authors

Ewa Sierko

References (76)
  1. Stone HB, Peters LJ, Milas L. Effect of host immune capability on radiocurability and subsequent translatability of a murine fibrosarcoma. J Natl Cancer Inst. 1979; 63: 1229–35.
  2. Dar TB, Henson RM, Shiao SL. Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy. Front Immunol. 2018; 9: 3077.
    CrossRefPubMed
  3. Lugade AA, Sorensen EW, Gerber SA, et al. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008; 180(5): 3132–3139.
    CrossRefPubMed
  4. Shiao SL, Ruffell B, DeNardo DG, et al. TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy. Cancer Immunol Res. 2015; 3(5): 518–525.
    CrossRefPubMed
  5. Palucka AK, Coussens LM. The Basis of Oncoimmunology. Cell. 2016; 164(6): 1233–1247.
    CrossRefPubMed
  6. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1): 1–10.
    CrossRefPubMed
  7. Boon T, Cerottini JC, Van den Eynde B, et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994; 12: 337–365.
    CrossRefPubMed
  8. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21(3): 309–322.
    CrossRefPubMed
  9. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21(2): 137–148.
    CrossRefPubMed
  10. Garg AD, Agostinis P. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunol Rev. 2017; 280(1): 126–148.
    CrossRefPubMed
  11. Yang M, McKay D, Pollard JW, et al. Diverse Functions of Macrophages in Different Tumor Microenvironments. Cancer Res. 2018; 78(19): 5492–5503.
    CrossRefPubMed
  12. Deng L, Liang H, Xu M, et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014; 41(5): 843–852.
    CrossRefPubMed
  13. Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010; 2(63): 63ra94.
    CrossRefPubMed
  14. Deng L, Liang H, Fu S, et al. From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy. Clin Cancer Res. 2016; 22(1): 20–25.
    CrossRefPubMed
  15. Chen Qi, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016; 17(10): 1142–1149.
    CrossRefPubMed
  16. Woo SR, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014; 41(5): 830–842.
    CrossRefPubMed
  17. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008; 455(7213): 674–678.
    CrossRefPubMed
  18. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009; 461(7265): 788–792.
    CrossRefPubMed
  19. Li T, Chen ZJ. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med. 2018; 215(5): 1287–1299.
    CrossRefPubMed
  20. Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017; 8: 15618.
    CrossRefPubMed
  21. Brandmaier A, Formenti SC. The Impact of Radiation Therapy on Innate and Adaptive Tumor Immunity. Semin Radiat Oncol. 2020; 30(2): 139–144.
    CrossRefPubMed
  22. Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med. 2008; 14(6): 623–628.
    CrossRefPubMed
  23. Ostrand-Rosenberg S, Horn LA, Ciavattone NG. Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy. Front Oncol. 2019; 9: 215.
    CrossRefPubMed
  24. Liu Y, Dong Y, Kong Li, et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018; 11(1): 104.
    CrossRefPubMed
  25. Demaria S, Formenti SC. The abscopal effect 67 years later: from a side story to center stage. Br J Radiol. 2020; 93(1109): 20200042.
    CrossRefPubMed
  26. Dutt S, Ahmed MM, Loo BW, et al. Novel Radiation Therapy Paradigms and Immunomodulation: Heresies and Hope. Semin Radiat Oncol. 2020; 30(2): 194–200.
    CrossRefPubMed
  27. Arina A, Gutiontov SI, Weichselbaum RR. Radiotherapy and Immunotherapy for Cancer: From "Systemic" to "Multisite". Clin Cancer Res. 2020; 26(12): 2777–2782.
    CrossRefPubMed
  28. Lan J, Li R, Yin LM, et al. Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018; 101(1): 74–87.
    CrossRefPubMed
  29. Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol. 2019; 16(2): 123–135.
    CrossRefPubMed
  30. Theelen WS, Peulen HMU, Lalezari F, et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019; 5(9): 1276–1282.
    CrossRefPubMed
  31. Luke JJ, Lemons JM, Karrison TG, et al. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018; 36(16): 1611–1618.
    CrossRefPubMed
  32. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009; 15(17): 5379–5388.
    CrossRefPubMed
  33. Diamond JM, Vanpouille-Box C, Spada S, et al. Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs. Cancer Immunol Res. 2018; 6(8): 910–920.
    CrossRefPubMed
  34. Menon H, Chen D, Ramapriyan R, et al. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer. 2019; 7(1): 237.
    CrossRefPubMed
  35. Barsoumian HB, Ramapriyan R, Younes AI, et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020; 8(2).
    CrossRefPubMed
  36. McGee HM, Daly ME, Azghadi S, et al. Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. Int J Radiat Oncol Biol Phys. 2018; 101(5): 1259–1270.
    CrossRefPubMed
  37. Käsmann L, Eze C, Manapov F. Stereotactic Body Radiation Therapy (SBRT) Combined with Immune Check-Point Inhibition (ICI) in Advanced Lung Cancer: Which Metastatic Site Should Be Irradiated to Induce Immunogenic Cell Death? Int J Radiat Oncol Biol Phys. 2020; 108(1): 225–226.
    CrossRefPubMed
  38. Lambin P, Lieverse RIY, Eckert F, et al. Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyte-rich Organs When Combining Radiotherapy With Immunotherapy. Semin Radiat Oncol. 2020; 30(2): 187–193.
    CrossRefPubMed
  39. Kuncman Ł, Pietrzykowska-Kuncman M, Danielska J, et al. Bone marrow sparing RT in era of immunotherapy. Nowotwory. Journal of Oncology. 2018; 67(5): 301–307.
    CrossRef
  40. Tubin S, Popper HH, Brcic L. Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects. Radiat Oncol. 2019; 14(1): 21.
    CrossRefPubMed
  41. Lussier DM, Alspach E, Ward JP, et al. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc Natl Acad Sci U S A. 2021; 118(24).
    CrossRefPubMed
  42. Williamson CW, Sherer MV, Zamarin D, et al. Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety. Cancer. 2021; 127(10): 1553–1567.
    CrossRefPubMed
  43. Ho AY, Wright JL, Blitzblau RC, et al. Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2020; 108(1): 227–241.
    CrossRefPubMed
  44. Aliru ML, Schoenhals JE, Venkatesulu BP, et al. Radiation therapy and immunotherapy: what is the optimal timing or sequencing? Immunotherapy. 2018; 10(4): 299–316.
    CrossRefPubMed
  45. Young KH, Baird JR, Savage T, et al. Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy. PLoS One. 2016; 11(6): e0157164.
    CrossRefPubMed
  46. Qian JM, Yu JB, Kluger HM, et al. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer. 2016; 122(19): 3051–3058.
    CrossRefPubMed
  47. Kiess AP, Wolchok JD, Barker CA, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015; 92(2): 368–375.
    CrossRefPubMed
  48. Jiang W, Rodriguez Y, Kim B, et al. Temporally-Dependent Intracranial Control of Melanoma Brain Metastasis by Stereotactic Radiation Therapy in Patients Treated With Immune Checkpoint Blockade. Int J Radiat Oncol Biol Phys. 2015; 93(3): S57.
    CrossRef
  49. Barker CA, Postow MA, Khan SA, et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res. 2013; 1(2): 92–98.
    CrossRefPubMed
  50. Knisely JPS, Yu JB, Flanigan J, et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012; 117(2): 227–233.
    CrossRefPubMed
  51. Vos JL, Elbers JBW, Krijgsman O, et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat Commun. 2021; 12(1): 7348.
    CrossRefPubMed
  52. Salama AKS, Palta M, Rushing CN, et al. Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma. Clin Cancer Res. 2021; 27(5): 1287–1295.
    CrossRefPubMed
  53. Mayadev JS, Enserro D, Lin YG, et al. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA Oncol. 2020; 6(1): 92–99.
    CrossRefPubMed
  54. Verbrugge I, Hagekyriakou J, Sharp LL, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 2012; 72(13): 3163–3174.
    CrossRefPubMed
  55. Sharabi AB, Nirschl CJ, Kochel CM, et al. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res. 2015; 3(4): 345–355.
    CrossRefPubMed
  56. Theelen WS, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021; 9(5): 467–475.
    CrossRefPubMed
  57. Theelen WS, Peulen HMU, Lalezari F, et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019; 5(9): 1276–1282.
    CrossRefPubMed
  58. Peters S, Felip E, Dafni U, et al. Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). J Thorac Oncol. 2021; 16(2): 278–288.
    CrossRefPubMed
  59. Shaverdian N, Lisberg A, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017; 18(7): 895–903.
    CrossRef
  60. https://clinicaltrials.gov/ct2/results?cond=&term=NCT03700905&cntry=&state=&city=&dist=.
  61. https://clinicaltrials.gov/ct2/results?cond=&term=NCT04365036&cntry=&state=&city=&dist=.
  62. https://clinicaltrials.gov/ct2/results?cond=&term=NCT+04221945&cntry=&state=&city=&dist=.
  63. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014; 74(19): 5458–5468.
    CrossRefPubMed
  64. Azad A, Yin Lim Su, D'Costa Z, et al. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med. 2017; 9(2): 167–180.
    CrossRefPubMed
  65. Socinski MA, Özgüroğlu M, Villegas A, et al. PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20): 1919–1929.
    CrossRefPubMed
  66. Gray JE, Villegas A, Daniel D, et al. PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018; 379(24): 2342–2350.
    CrossRefPubMed
  67. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(12): 1301–1311.
    CrossRefPubMed
  68. https://clinicaltrials.gov/ct2/show/NCT04786093?term=durvalumab+radiation+therapy&draw=2&rank=6.
  69. https://clinicaltrials.gov/ct2/show/NCT03830866?term=NCT+03830866&draw=2&rank=1.
  70. https://clinicaltrials.gov/ct2/show/NCT04786093?term=NCT04786093&draw=2&rank=1.
  71. Sha CM, Lehrer EJ, Hwang C, et al. Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis. Radiother Oncol. 2020; 151: 141–148.
    CrossRefPubMed
  72. Anscher MS, Arora S, Weinstock C, et al. Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration Database. JAMA Oncol. 2022; 8(2): 232–240.
    CrossRefPubMed
  73. Schoenfeld JD, Mahadevan A, Floyd SR, et al. Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer. 2015; 3: 50.
    CrossRefPubMed
  74. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009; 15(17): 5591–5598.
    CrossRefPubMed
  75. Mathew M, Tam M, Ott PA, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 2013; 23(3): 191–195.
    CrossRefPubMed
  76. Bourke JM, O'Sullivan M, Khattak MA. Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors). Med J Aust. 2016; 205(9): 418–424.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl